Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy

HYERA KIM, SEUNG TAE KIM, KWAI HAN YOO, JUNG YONG HONG, YOUNG SUK PARK, HO YEONG LIM and JOON OH PARK
In Vivo January 2021, 35 (1) 499-505; DOI: https://doi.org/10.21873/invivo.12284
HYERA KIM
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
2Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SEUNG TAE KIM
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KWAI HAN YOO
3Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JUNG YONG HONG
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
YOUNG SUK PARK
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HO YEONG LIM
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
JOON OH PARK
1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: oncopark{at}skku.edu
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 35 no. 1 499-505
DOI 
https://doi.org/10.21873/invivo.12284
PMID 
33402502

Published By 
International Institute of Anticancer Research
Print ISSN 
0258-851X
Online ISSN 
1791-7549
History 
  • Received October 12, 2020
  • Revision received November 2, 2020
  • Accepted November 4, 2020
  • Published online January 5, 2021.

Copyright & License 
Copyright © 2021 The Author(s). Published by the International Institute of Anticancer Research.

Author Information

  1. HYERA KIM1,2,*,
  2. SEUNG TAE KIM1,*,
  3. KWAI HAN YOO3,*,
  4. JUNG YONG HONG1,
  5. YOUNG SUK PARK1,
  6. HO YEONG LIM1 and
  7. JOON OH PARK1⇑
  1. 1Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea;
  2. 2Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea;
  3. 3Division of Hematology and Oncology, Department of Internal Medicine, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Republic of Korea
  1. Correspondence to: Joon Oh Park, Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea. Tel: +82 234103457, Fax: +82 234101754, e-mail: oncopark{at}skku.edu
  1. ↵* These Authors contributed equally to this article.

View Full Text

Statistics from Altmetric.com

Cited By...

  • 2 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

In Vivo
Vol. 35, Issue 1
January-February 2021
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
1 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
HYERA KIM, SEUNG TAE KIM, KWAI HAN YOO, JUNG YONG HONG, YOUNG SUK PARK, HO YEONG LIM, JOON OH PARK
In Vivo Jan 2021, 35 (1) 499-505; DOI: 10.21873/invivo.12284

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
HYERA KIM, SEUNG TAE KIM, KWAI HAN YOO, JUNG YONG HONG, YOUNG SUK PARK, HO YEONG LIM, JOON OH PARK
In Vivo Jan 2021, 35 (1) 499-505; DOI: 10.21873/invivo.12284
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • Real-world Analysis of Treatment Patterns, Clinical Outcomes, and Molecular Profiling in Advanced Biliary Tract Cancer
  • Google Scholar

More in this TOC Section

  • Clinical Evaluation Versus Clinical Evaluation With Dermoscopy in Malignant Skin Neoplasms Diagnosis
  • Clinical Utility of Body Weight Monitoring During Cisplatin-based Chemotherapy
  • NLRP3 and RANK-RANKL-OPG Pathway-related Gene Expression Levels in Children With Autism Spectrum Disorder
Show more Clinical Studies

Keywords

  • Biliary tract cancer
  • ATM
  • prognosis
In Vivo

© 2026 In Vivo

Powered by HighWire